Immuneering Co. (NASDAQ:IMRX - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,760,000 shares, a decline of 23.1% from the December 15th total of 2,290,000 shares. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is presently 0.8 days. Currently, 7.9% of the company's shares are sold short.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on IMRX. Needham & Company LLC restated a "buy" rating and issued a $15.00 price objective on shares of Immuneering in a report on Monday. Morgan Stanley downgraded shares of Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th. Finally, Chardan Capital restated a "buy" rating and set a $13.00 price objective on shares of Immuneering in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $12.80.
View Our Latest Stock Analysis on Immuneering
Immuneering Stock Up 3.2 %
IMRX stock traded up $0.06 during mid-day trading on Thursday, reaching $1.96. The company had a trading volume of 814,448 shares, compared to its average volume of 9,335,315. Immuneering has a one year low of $1.00 and a one year high of $7.68. The stock's 50-day simple moving average is $2.05 and its two-hundred day simple moving average is $1.79. The stock has a market capitalization of $60.86 million, a P/E ratio of -0.99 and a beta of -0.34.
Institutional Trading of Immuneering
Institutional investors and hedge funds have recently bought and sold shares of the stock. Corsair Capital Management L.P. acquired a new position in Immuneering in the third quarter worth approximately $25,000. Vontobel Holding Ltd. acquired a new stake in shares of Immuneering in the third quarter valued at $25,000. XTX Topco Ltd boosted its holdings in Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company's stock valued at $44,000 after acquiring an additional 9,274 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Immuneering in the second quarter valued at about $44,000. Finally, Tidemark LLC bought a new position in Immuneering during the third quarter worth about $129,000. Institutional investors and hedge funds own 67.65% of the company's stock.
About Immuneering
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
See Also
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
